Wilms' tumor 1 peptide-loaded dendritic cell vaccination in patients with relapsed or refractory acute leukemia.
Ther Apher Dial
; 26(3): 537-547, 2022 Jun.
Article
em En
| MEDLINE
| ID: mdl-35249263
ABSTRACT
INTRODUCTION:
The prognosis of patients with relapsed or refractory acute leukemia is poor. In the present pilot study, we treated relapsed or refractory acute leukemia patients with Wilms' tumor 1 (WT1) peptide-loaded dendritic cells (DCs) and examined safety, clinical and immunological responses.METHODS:
Eleven eligible patients were enrolled. DCs were administered every 2-3 weeks with OK-432 adjuvant.RESULTS:
The treatment was well tolerated. The reduction of leukemia cells or the expression of WT1 mRNA was observed in four patients which was maintained for a significant period of time. All the responding patients manifested immune responses against WT1 which might be related to clinical outcome. Decreases in the absolute number of regulatory T cells were observed following vaccination, indicating that DC vaccinations may contribute to the reversal of immunosuppression.CONCLUSION:
These results indicate that DC-based immunotherapy is safe and feasible for patients with acute leukemia.Palavras-chave
Texto completo:
1
Coleções:
01-internacional
Contexto em Saúde:
2_ODS3
Base de dados:
MEDLINE
Assunto principal:
Leucemia
/
Proteínas WT1
Limite:
Humans
Idioma:
En
Revista:
Ther Apher Dial
Ano de publicação:
2022
Tipo de documento:
Article